Kola A, Baensch M, Bautsch W, Hennecke M, Klos A, Casaretto M, Köhl J
Institut für Medizinische Mikrobiologie, Medizinische Hochschule Hannover, Germany.
Immunotechnology. 1996 Jun;2(2):115-26. doi: 10.1016/1380-2933(96)00425-3.
The anaphylatoxin C5a is a powerful proinflammatory protein generated on activation of the complement system. Recently, we described an anti-hC5a neoepitope specific mAb, mAb 2925, which was raised against the nonapeptide ISHKDMQLG (C5a-(65-73). This mAb is unique in that it recognizes both hC5a and hC5adesArg, even when it is denatured. It inhibits binding of [125I]C5a to its receptor on Bt2-cAMP differentiated U937 cells.
To define the epitope of mAb 2925, we used a combined approach of a bacteriophage random octapeptide library, synthetic peptides and site-directed mutagenesis.
First a phage peptide library was screened with the anti C5a mAb 2925. Then synthetic peptides were synthesized with respect to the sequence information yielded from the phage approach, and used for binding studies. Site-directed mutagenesis was performed to confirm the results from the mapping experiments.
Most phages selected by biotinylated Fab 2925 displayed sequences on the minor coat protein which correspond to residues within the C-terminus of human C5a. A first consensus motif comprised amino acids His-Lys or His-Arg, which allowed us to define position 67 and 68 as part of the epitope. A second consensus motif was selected, comprising Arg/Lys-Trp-Trp. This motif did not match any residues within the C5a C-terminus. However, when expressed together with the consensus motif His-Arg, as in HRWWXXXX or in HRXKWWXX, binding of these peptides to Fab 2925 increased as compared to peptides expressing the His-Arg motif only. Thus, the Arg/Lys-Trp-Trp motif serves to stabilize the binding of His-Arg to mAb 2925. Synthetic peptide studies revealed further N-terminal residues Ile65 and Ser66 as part of the epitope. A C5a mutant with an exchange Lys68Glu (C5aGlu68) confirmed the participation of Lys68 as a contact residue within the epitope of mAb 2925. Hence, the epitope recognized by mAb 2925 is linear and comprises residues Ile65, Ser66, His67, and Lys68. Thus, we could demonstrate for the first time that a mAb inhibits C5a receptor binding through specific interaction with receptor binding residues of the ligand.
过敏毒素C5a是补体系统激活后产生的一种强大的促炎蛋白。最近,我们描述了一种抗人C5a新表位特异性单克隆抗体mAb 2925,它是针对九肽ISHKDMQLG(C5a-(65 - 73))产生的。这种单克隆抗体的独特之处在于,即使在变性状态下,它也能识别hC5a和hC5adesArg。它能抑制[125I]C5a与其在Bt2 - cAMP分化的U937细胞上的受体结合。
为了确定mAb 2925的表位,我们采用了噬菌体随机八肽文库、合成肽和定点诱变相结合的方法。
首先用抗C5a单克隆抗体mAb 2925筛选噬菌体肽文库。然后根据噬菌体方法得到的序列信息合成合成肽,并用于结合研究。进行定点诱变以确认定位实验的结果。
生物素化的Fab 2925筛选出的大多数噬菌体在次要外壳蛋白上显示的序列与人C5a C末端的残基相对应。第一个共有基序包含氨基酸His - Lys或His - Arg,这使我们能够将第67和68位定义为表位的一部分。选择了第二个共有基序,包括Arg/Lys - Trp - Trp。这个基序与C5a C末端的任何残基都不匹配。然而,当与共有基序His - Arg一起表达时,如在HRWWXXXX或HRXKWWXX中,与仅表达His - Arg基序的肽相比,这些肽与Fab 2925的结合增加。因此,Arg/Lys - Trp - Trp基序用于稳定His - Arg与mAb 2925的结合。合成肽研究揭示了表位的其他N末端残基Ile65和Ser66。一个将Lys68替换为Glu的C5a突变体(C5aGlu68)证实了Lys68作为mAb 2925表位内的一个接触残基的参与。因此,mAb 2925识别的表位是线性的,包含残基Ile65、Ser66、His67和Lys68。因此,我们首次证明了一种单克隆抗体通过与配体的受体结合残基特异性相互作用来抑制C5a受体结合。